Literature DB >> 31113610

Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis.

Dahai Xu1, Chang Su2, Liang Sun3, Yuanyuan Gao3, Youjun Li4.   

Abstract

INTRODUCTION AND AIM: Serum glypican-3 (GPC3) has been explored as a non-invasive biomarker of hepatocellular carcinoma (HCC). However, controversy remains on its diagnostic accuracy. Therefore, we aimed to conduct a systematic review and metaanalysis to evaluate the differential diagnostic accuracy of serum GPC3 between HCC and liver cirrhosis (LC) cases.
MATERIAL AND METHODS: After the strict filtering and screening of studies from NCBI, PUBMED, Clinical Trials, Cochrane library, Embase, Prospero and Web of Science databases, 11 studies were selected. All studies provided the sensitivity and specificity of GPC3 and the alpha-fetoprotein (AFP) in the HCC and LC diagnosis. The sensitivity and specificity, and the area under the receiver operating characteristic curve (AUC) were determined and compared between GPC3 and AFP, which was set as a positive control.
RESULTS: Pooled sensitivity (95% CI) and specificity (95% CI) were 0.55 (0.52-0.58) and 0.58 (0.54-0.61) for GPC3, 0.54 (0.51-0.57) and 0.83 (0.80-0.85) for AFP, and 0.85 (0.81-0.89) and 0.79 (0.73-0.84) for GPC3 + AFP, respectively. The AUCs of GPC3, AFP and GPC3 + AfP were 0.7793, 0.7867 and 0.9366, respectively. GPC3 had a nearly similar sensitivity as AFP, while the specificity and AUC of GPC3 was lower than that of AFP. The combination of GPC3 and AFP yielded a better sensitivity and AUC than GPC3 or AFP.
CONCLUSION: Serum GPC3 is inferior to AFP in the differential diagnosis between HCC and LC. However, the combination of GPC3 and AFP exhibited a much better performance.
Copyright © 2019 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Alpha fetoprotein; Biomarker; Liver cirrhosis; Sensitivity; Specificity

Mesh:

Substances:

Year:  2019        PMID: 31113610     DOI: 10.5604/01.3001.0012.7863

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  19 in total

1.  Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression.

Authors:  Neven A Hagag; Yasser B M Ali; Ahmed A Elsharawy; Roba M Talaat
Journal:  J Gastrointest Cancer       Date:  2020-03

Review 2.  Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma.

Authors:  Philip Johnson; Qing Zhou; Doan Y Dao; Y M Dennis Lo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-06-08       Impact factor: 73.082

Review 3.  A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook.

Authors:  Anna Kramvis; Kyong-Mi Chang; Maura Dandri; Patrizia Farci; Dieter Glebe; Jianming Hu; Harry L A Janssen; Daryl T Y Lau; Capucine Penicaud; Teresa Pollicino; Barbara Testoni; Florian Van Bömmel; Ourania Andrisani; Maria Beumont-Mauviel; Timothy M Block; Henry L Y Chan; Gavin A Cloherty; William E Delaney; Anna Maria Geretti; Adam Gehring; Kathy Jackson; Oliver Lenz; Mala K Maini; Veronica Miller; Ulrike Protzer; Jenny C Yang; Man-Fung Yuen; Fabien Zoulim; Peter A Revill
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-07-20       Impact factor: 73.082

4.  Generation of Dual functional Nanobody-Nanoluciferase Fusion and its potential in Bioluminescence Enzyme Immunoassay for trace Glypican-3 in Serum.

Authors:  Sheng Yu; Zhenfeng Li; Jingzhang Li; Shimei Zhao; Shanguang Wu; Hongjing Liu; Xiongjie Bi; Dongyang Li; Jiexian Dong; Siliang Duan; Bruce D Hammock
Journal:  Sens Actuators B Chem       Date:  2021-03-02       Impact factor: 9.221

Review 5.  Circulating biomarkers for early detection of hepatocellular carcinoma.

Authors:  Boris J B Beudeker; Andre Boonstra
Journal:  Therap Adv Gastroenterol       Date:  2020-06-29       Impact factor: 4.409

Review 6.  Glypican 3-Targeted Therapy in Hepatocellular Carcinoma.

Authors:  Takahiro Nishida; Hiroaki Kataoka
Journal:  Cancers (Basel)       Date:  2019-09-10       Impact factor: 6.639

7.  Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Gian Paolo Caviglia; Angelo Armandi; Chiara Rosso; Silvia Gaia; Serena Aneli; Emanuela Rolle; Maria Lorena Abate; Antonella Olivero; Aurora Nicolosi; Marta Guariglia; Davide Giuseppe Ribaldone; Patrizia Carucci; Giorgio Maria Saracco; Elisabetta Bugianesi
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

8.  Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma.

Authors:  Meng-Yuan Yang; Fan Wu; Feng Fang; Hao Yang; Jing-Fan Zhang; Guo-Dong Chen; Lian-Yue Yang
Journal:  BMC Cancer       Date:  2021-07-03       Impact factor: 4.430

9.  Diagnostic value of fibrinogen to prealbumin ratio and gamma-glutamyl transpeptidase to platelet ratio in the progression of AFP-negative hepatocellular carcinoma.

Authors:  Li Huang; Zhuning Mo; Zuojian Hu; Linyan Zhang; Shanzi Qin; Xue Qin; Shan Li
Journal:  Cancer Cell Int       Date:  2020-03-12       Impact factor: 5.722

10.  Diagnostic value of gamma-glutamyl transpeptidase to alkaline phosphatase ratio combined with gamma-glutamyl transpeptidase to aspartate aminotransferase ratio and alanine aminotransferase to aspartate aminotransferase ratio in alpha-fetoprotein-negative hepatocellular carcinoma.

Authors:  Jiang Li; Haisu Tao; Erlei Zhang; Zhiyong Huang
Journal:  Cancer Med       Date:  2021-06-18       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.